Biosergen AB Logo

Biosergen AB

Develops drugs to treat severe and resistant invasive fungal infections.

BIOSGN | ST

Overview

Corporate Details

ISIN(s):
SE0016013460 (+2 more)
LEI:
549300YD2OGUE7BMP925
Country:
Sweden
Address:
Fogdevreten 2, 171 65 Solna

Description

Biosergen AB is a clinical-stage biotechnology company developing innovative drugs to treat severe and resistant invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, broad-spectrum polyene macrolide. It is designed to be fungicidal, killing the fungus rather than only inhibiting its growth, and aims to provide a superior safety and potency profile compared to existing treatments. The primary target patient population is immunocompromised individuals, such as those with cancer, AIDS, or who have undergone organ transplants. BSG005 has completed a Phase 1 safety study and is advancing in clinical development. The candidate has received Orphan Drug Designation from the U.S. FDA and is protected by patents until 2043.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biosergen AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biosergen AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celemics, Inc. Logo
Develops NGS target enrichment solutions for research and clinical applications.
South Korea
331920
Develops radiopharmaceuticals and radioligand therapies for oncology.
South Korea
308430
CELL BIOTECH CO ., LTD Logo
Develops and manufactures probiotic solutions using patented dual-coating technology.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based immunotherapies for severe inflammatory and allergic diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Clinical-stage biopharma developing targeted cancer treatments via a PDC platform.
United States of America
CLRB
Cellectis Logo
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
France
ALCLS
Cellid Co., Ltd. Logo
Develops immunotherapeutic vaccines for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Researches and develops health foods, derma-cosmetics, and OTC pharmaceuticals.
South Korea
471820
CellSeed Inc. Logo
Develops and commercializes cell sheet engineering for regenerative medicine.
Japan
7776
Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.